FRNM
NASDAQ HealthcareFreenome, Inc. - Common stock
Diagnostics & Research
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreenย CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.
๐ Market Data
| Price | $12.86 |
|---|---|
| Volume | 359,659 |
| Market Cap | 1.38B |
| Beta | 0.450 |
| RSI (14-Day) | 34.1 |
| 200-Day MA | $12.52 |
| 50-Day MA | $14.76 |
| 52-Week High | $17.50 |
| 52-Week Low | $9.95 |
| Forward P/E | -5.36 |
| Price / Book | -0.24 |
๐ฏ Investment Strategy Scores
FRNM scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (74/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Over-Hyped (12/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find FRNM in your text
Paste any article, transcript, or post โ the tool will extract FRNM and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-10-29.